BTAI Stock Summary and Trading Ideas (Bioxcel Therapeutics | NASDAQ:BTAI)

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Bioxcel Therapeutics trades on the NASDAQ stock market under the symbol BTAI.

As of January 13, 2026, BTAI stock price climbed to $2.05 with 496,252 million shares trading.

BTAI has a beta of 2.61, meaning it tends to be more sensitive to market movements. BTAI has a correlation of 0.07 to the broad based SPY ETF.

BTAI has a market cap of $44.83 million. This is considered a Sub-Micro Cap stock.

Last quarter Bioxcel Therapeutics reported $98,000 in Revenue and -$2.18 earnings per share. This fell short of revenue expectation by $-92,002 and missed earnings estimates by -$.76.

In the last 3 years, BTAI traded as high as $546.00 and as low as $1.17.

The top ETF exchange traded funds that BTAI belongs to (by Net Assets): VXF.

BTAI has underperformed the market in the last year with a return of -66.0%, while the SPY ETF gained +20.8%. In the last 3 month period, BTAI fell short of the market, returning -19.3%, while SPY returned +6.5%. However, in the most recent 2 weeks BTAI has outperformed the stock market by returning +31.4%, while SPY returned +0.9%.

BTAI support price is $1.92 and resistance is $2.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BTAI shares will trade within this expected range on the day.